Navigation Links
MacroGenics Appoints New Vice President of Business Development

ROCKVILLE, Md., March 26 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the appointment of Eric Risser as Vice President, Business Development. "I am very pleased that we have been able to attract another exceptionally talented professional to the management team at MacroGenics," said Dr. Scott Koenig, President and CEO. "Eric has spent the last 15 years focused on life sciences; his skills will complement our management team's expertise as we position our company for growth and advance our pipeline towards commercialization."

Mr. Risser brings a wealth of strategic and transactional experience. Prior to joining MacroGenics, he served as Senior Director, Business Development at Johnson & Johnson Pharmaceuticals, which he joined in 2003. While at Johnson & Johnson, he was responsible for leading global transactions in the pharmaceuticals area, including company acquisitions, product licenses and research collaborations. His areas of expertise include originating collaboration opportunities, managing multi-disciplinary project teams, structuring and negotiating transactions, and formulating integration and alliance management plans.

Before Johnson & Johnson, Mr. Risser started and built a successful consulting practice that provided counsel to emerging life science companies in the United States and Europe. He has also worked as a venture capitalist with BankAmerica Ventures as an investment banker with Lehman Brothers, where he began his career in their New York and London offices. Mr. Risser holds an M.B.A. from Stanford University and a B.A. from Yale University.

"Eric joins us at an important time in MacroGenics' growth as a company. His business development expertise and skill set will be especially important as we seek global partners for our innovative antibody platform technologies and large library of antibodies that target cancers," stated Dr. Koenig.

About MacroGenics, Inc.

Founded in 2000, MacroGenics is a private, fully-integrated biotechnology company headquartered in Rockville, Maryland that focuses on the development, manufacture and commercialization of immunotherapeutics for autoimmune disorders, cancer and infectious diseases. In October 2007, MacroGenics, Inc. and Eli Lilly and Company announced a global strategic alliance to develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next-generation anti-CD3 molecules for use in the treatment of autoimmune diseases. Teplizumab is currently being studied in the PROTEGE trial, a global pivotal Phase II/III clinical trial for individuals with recent-onset type 1 diabetes (for more information, please visit In July 2008, MacroGenics acquired Raven Biotechnologies, Inc., a privately held biotechnology company in South San Francisco, California, focused on the discovery and development of monoclonal antibody therapeutics for oncology through its cancer stem-like cell program. MacroGenics' proprietary DART (Dual Affinity Re-Targeting) and Fc-optimization technologies offer ways to improve the function of antibodies and similar molecules. For more information about MacroGenics, please visit

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, and risks related to the Company's ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.

SOURCE MacroGenics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. MacroGenics Raises $25M in Series D-2 Financing
2. MacroGenics Acquires Raven Biotechnologies
3. Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman
4. DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors
5. DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
6. Veridiam Appoints Andrew Gale as Chief Executive Officer
7. Pharmaxis Appoints French Distributor for Aridol(TM)
8. Lakewood-Amedex, Inc. Appoints William J. Robison, Former Executive Vice President of Pfizer, as Board Member
9. PURE Bioscience Board Appoints John J. Carbone, MD to Board of Directors
10. China-Biotics, Inc. Appoints New Chief Financial Officer
11. Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board
Post Your Comments:
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
Breaking Biology News(10 mins):